Coyote Bioscience
Beijing, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
Developer of rapid molecular diagnostic platforms for infectious diseases and genetic analysis.
Infectious DiseaseDiagnosticsGenetics & Genomics
Technology Platform
Proprietary isothermal nucleic acid amplification and integrated microfluidic cartridge system for rapid, point-of-care molecular diagnostics.
Opportunities
Expansion into decentralized testing for chronic disease management and international market penetration present significant growth avenues.
Risk Factors
Heavy reliance on infectious disease testing sales, which may fluctuate post-pandemic, and intense price competition are key risks.
Competitive Landscape
Faces intense competition in the crowded Chinese molecular diagnostics market from giants like BGI and numerous other platform companies.